Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas

OncoImmunology

Volumn 2, Issue 12, 2013, Pages 1-9

  Sow, Heng Sheng ^a   Mattarollo, Stephen R ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Anticancer vaccines; Immunotherapy; Low dose chemotherapy; Lymphoma; Metronomic chemotherapy

Indexed keywords

BEVACIZUMAB; BLEOMYCIN; CANCER VACCINE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DENDRITIC CELL VACCINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; LOMUSTINE; LYMPHOMA VACCINE; METHOTREXATE; OLIGODEOXYNUCLEOTIDE DERIVATIVE; PREDNISONE; PROCARBAZINE; ROFECOXIB; VINBLASTINE; VINCRISTINE;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL MEDIATED CYTOTOXICITY; CELL POPULATION; DOWN REGULATION; DRUG EFFICACY; DRUG RESPONSE; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; METRONOMIC DRUG ADMINISTRATION; MULTIPLE CYCLE TREATMENT; MYELOID PROGENITOR CELL; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; TUMOR REGRESSION; TUMOR VASCULARIZATION; UPREGULATION;

EID: 84894582150     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27058     Document Type: Review

References (80)

1. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet 2012; 380:848-57; PMID:22835603; http://dx.doi.org/10.1016/ S0140-6736(12)60605-9
2. Gandhi MK, Marcus RE. Follicular lymphoma: time for a re-think? Blood Rev 2005; 19:165-78; PMID:15748964; http://dx.doi.org/10.1016/j. blre.2004.09.001
3. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106:3725-32; PMID:16123223; http://dx.doi. org/10.1182/blood-2005-01-0016
4. Krause SW, Gerken M, Andreesen R, Hofstädter F, Klinkhammer-Schalke M. Treatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit can be demonstrated in the routine data of a regional cancer registry. Ann Hematol 2012; 91:561-70; PMID:22200972; http://dx.doi.org/10.1007/ s00277-011-1361-6
5. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 2005; 5:516-25; PMID:15965493; http://dx.doi.org/10.1038/nrc1650
6. Gasparini G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2001; 2:733-40; PMID:11902515; http://dx.doi.org/10.1016/ S1470-2045(01)00587-3
7. Mross K, Steinbild S. Metronomic anti-cancer therapy - an ongoing treatment option for advanced cancer patients. journal of Cancer Therapeutics and Research 2012:1
8. Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60:1878-86; PMID:10766175
9. Ménard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 2008; 57:1579-87; PMID:18369619; http://dx.doi. org/10.1007/s00262-008-0505-6
10. Poppema S, Visser L. Absence of HLA class I expression by Reed-Sternberg cells. Am J Pathol 1994; 145:37-41; PMID:7518195
11. Drénou B, Le Friec G, Bernard M, Pangault C, Grosset JM, Lamy T, Fauchet R, Amiot L. Major histocompatibility complex abnormalities in non-Hodgkin lymphomas. Br J Haematol 2002; 119:417-24; PMID:12406080; http://dx.doi. org/10.1046/j.1365-2141.2002.03814.x
12. Liu WM, Fowler DW, Smith P, Dalgleish AG. Pretreatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 2010; 102:115-23; PMID:19997099; http://dx.doi. org/10.1038/sj.bjc.6605465
13. Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, Sanchez M, Lorenzi S, D'Urso MT, Belardelli F, et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res 2011; 71:768-78; PMID:21156650; http://dx.doi.org/10.1158/0008-5472.CAN-10-2788
14. Aymeric L, Apetoh L, Ghiringhelli F, Tesniere A, Martins I, Kroemer G, Smyth MJ, Zitvogel L. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res 2010; 70:855-8; PMID:20086177; http://dx.doi. org/10.1158/0008-5472.CAN-09-3566
15. Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S, Altiok S, Celis E, Gabrilovich DI. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2010; 120:1111-24; PMID:20234093; http://dx.doi.org/10.1172/ JCI40269
16. Zoi-Toli O, Vermeer MH, De Vries E, Van Beek P, Meijer CJ, Willemze R. Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL. Br J Dermatol 2000; 143:313-9; PMID:10951138; http://dx.doi. org/10.1046/j.1365-2133.2000.03656.x
17. Pospisilova J, Vit O, Lorkova L, Klanova M, Zivny J, Klener P, Petrak J. Resistance to TRAIL in mantle cell lymphoma cells is associated with the decreased expression of purine metabolism enzymes. Int J Mol Med 2013; 31:1273-9; PMID:23503700
18. Akiyama H, Ino T, Tokunaga E, Katsuda I, Ezaki K. A synergistic increase of apoptosis utilizing Fas antigen expression induced by low doses of anticancer drug. Rinsho Byori 2003; 51:733-9; PMID:13677932
19. Wu XX, Jin XH, Zeng Y, El Hamed AM, Kakehi Y. Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression. Cancer Sci 2007; 98:1969-76; PMID:17922852; http://dx.doi.org/10.1111/j.1349-7006.2007.00632.x
20. Mattarollo SR, Kenna T, Nieda M, Nicol AJ. Chemotherapy pretreatment sensitizes solid tumorderived cell lines to V alpha 24+ NKT cell-mediated cytotoxicity. Int J Cancer 2006; 119:1630-7; PMID:16646079; http://dx.doi.org/10.1002/ ijc.22019
21. Kang J, Bu J, Hao Y, Chen F. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP. Prostate Cancer Prostatic Dis 2005; 8:274-9; PMID:15897917; http://dx.doi.org/10.1038/ sj.pcan.4500798
22. van der Most RG, Currie AJ, Cleaver AL, Salmons J, Nowak AK, Mahendran S, Larma I, Prosser A, Robinson BWS, Smyth MJ, et al. Cyclophosphamide chemotherapy sensitizes tumor cells to TRAILdependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One 2009; 4:e6982; PMID:19746156; http://dx.doi. org/10.1371/journal.pone.0006982
23. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008; 27:5932-43; PMID:18836474; http://dx.doi.org/10.1038/ onc.2008.267
24. Konjevic G, Jurisic V, Banicevic B, Spuzic I. The difference in NK-cell activity between ptients with non-Hodgkin's lymphomas and Hodgkin's disease. Br J Haematol 1999; 104:144-51; PMID:10027727; http://dx.doi.org/10.1046/j.1365-2141.1999.01129.x
25. Reiners KS, Kessler J, Sauer M, Rothe A, Hansen HP, Reusch U, Hucke C, Kohl U, Durkop H, Engert A, et al. Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients. Molecular therapy. the journal of the American Society of Gene Therapy 2013; 21:895-903; http://dx.doi.org/10.1038/mt.2013.14
26. Zocchi MR, Catellani S, Canevali P, Tavella S, Garuti A, Villaggio B, Zunino A, Gobbi M, Fraternali-Orcioni G, Kunkl A, et al. High ERp5/ ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas. Blood 2012; 119:1479-89; PMID:22167753; http://dx.doi.org/10.1182/ blood-2011-07-370841
27. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419:734-8; PMID:12384702; http://dx.doi.org/10.1038/ nature01112
28. Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002; 169:4098-102; PMID:12370336
29. Hervieu A, Rébé C, Végran F, Chalmin F, Bruchard M, Vabres P, Apetoh L, Ghiringhelli F, Mignot G. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. J Invest Dermatol 2013; 133:499-508; PMID:22951720; http://dx.doi. org/10.1038/jid.2012.273
30. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V, Cippitelli M, Fionda C, Petrucci MT, Guarini A, et al. ATM-ATRdependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009; 113:3503-11; PMID:19098271; http://dx.doi. org/10.1182/blood-2008-08-173914
31. Zhang C, Zhang J, Sun R, Feng J, Wei H, Tian Z. Opposing effect of IFNgamma and IFNalpha on expression of NKG2 receptors: negative regulation of IFNgamma on NK cells. Int Immunopharmacol 2005; 5:1057-67; PMID:15829421; http://dx.doi. org/10.1016/j.intimp.2005.02.003
32. Zhang C, Zhang J, Niu J, Zhang J, Tian Z. Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation. Cytokine 2008; 42:128-36; PMID:18280748; http://dx.doi.org/10.1016/j. cyto.2008.01.003
33. Zhang C, Zhang J, Niu J, Zhou Z, Zhang J, Tian Z. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D. Hum Immunol 2008; 69:490-500; PMID:18619507; http://dx.doi.org/10.1016/j.humimm.2008.06.004
34. Park YP, Choi SC, Kiesler P, Gil-Krzewska A, Borrego F, Weck J, Krzewski K, Coligan JE. Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the ?c cytokines and TGF-ß1. Blood 2011; 118:3019-27; PMID:21816829; http:// dx.doi.org/10.1182/blood-2011-04-346825
35. Schiavoni G, Mattei F, Di Pucchio T, Santini SM, Bracci L, Belardelli F, Proietti E. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 2000; 95:2024-30; PMID:10706870
36. Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, Baccarini S, Maccari S, Ramoni C, Belardelli F, et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 2007; 13:644-53; PMID:17255288; http://dx.doi. org/10.1158/1078-0432.CCR-06-1209
37. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000; 101:455-8; PMID:10850488; http://dx.doi.org/10.1016/ S0092-8674(00)80856-9
38. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322:271-5; PMID:18845758; http://dx.doi.org/10.1126/science.1160062
39. Ohkusu-Tsukada K, Toda M, Udono H, Kawakami Y, Takahashi K. Targeted inhibition of IL-10-secreting CD25-Treg via p38 MAPK suppression in cancer immunotherapy. Eur J Immunol 2010; 40:1011-21; PMID:20127675; http://dx.doi.org/10.1002/ eji.200939513
40. Ghiringhelli F, Ménard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE, Novault S, Escudier B, Vivier E, et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 2005; 202:1075-85; PMID:16230475; http://dx.doi. org/10.1084/jem.20051511
41. Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004; 103:1755-62; PMID:14604957; http:// dx.doi.org/10.1182/blood-2003-07-2594
42. Mittal S, Marshall NA, Duncan L, Culligan DJ, Barker RN, Vickers MA. Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008; 111:5359-70; PMID:18305220; http://dx.doi.org/10.1182/ blood-2007-08-105395
43. Dou AX, Feng LL, Liu XQ, Wang X. Cyclic adenosine monophosphate involvement in low-dose cyclophosphamide-reversed immune evasion in a mouse lymphoma model. Cell Mol Immunol 2012; 9:482-8; PMID:23000689; http://dx.doi.org/10.1038/ cmi.2012.34
44. Tongu M, Harashima N, Yamada T, Harada T, Harada M. Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma. Cancer Immunol Immunother 2010; 59:769-77; PMID:19940990; http://dx.doi. org/10.1007/s00262-009-0797-1
45. Zhu Y, Liu N, Xiong SD, Zheng YJ, Chu YW. CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of toll-like receptor 4. Scand J Immunol 2011; 73:301-8; PMID:21223350; http:// dx.doi.org/10.1111/j.1365-3083.2011.02514.x
46. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http:// dx.doi.org/10.1038/nri2506
47. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111:4233-44; PMID:18272812; http:// dx.doi.org/10.1182/blood-2007-07-099226
48. Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, Villagra A, Antonia S, McCaffrey JC, Fishman M, et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol 2013; 14:211-20; PMID:23354483; http://dx.doi. org/10.1038/ni.2526
49. Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 2011; 11:802-7; PMID:21237299; http://dx.doi.org/10.1016/j. intimp.2011.01.003
50. Brandau S, Trellakis S, Bruderek K, Schmaltz D, Steller G, Elian M, Suttmann H, Schenck M, Welling J, Zabel P, et al. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol 2011; 89:311-7; PMID:21106641; http://dx.doi.org/10.1189/ jlb.0310162
51. Verma C, Eremin JM, Robins A, Bennett AJ, Cowley GP, El-Sheemy MA, Jibril JA, Eremin O. Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC. J Transl Med 2013; 11:16; PMID:23320561; http://dx.doi.org/10.1186/1479-5876-11-16
52. Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote crosstolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008; 68:5439-49; PMID:18593947; http://dx.doi.org/10.1158/0008-5472.CAN-07-6621
53. Schlecker E, Stojanovic A, Eisen C, Quack C, Falk CS, Umansky V, Cerwenka A. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol 2012; 189:5602-11; PMID:23152559; http://dx.doi.org/10.4049/ jimmunol.1201018
54. Schmid MC, Varner JA. Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J Oncol 2010; 2010:201026; PMID:20490273; http://dx.doi. org/10.1155/2010/201026
55. Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB. Immunosuppressive CD14+HLADR(low)/-monocytes in B-cell non-Hodgkin lymphoma. Blood 2011; 117:872-81; PMID:21063024; http://dx.doi.org/10.1182/blood-2010-05-283820
56. Parrinello N, La Cava P, Tibullo D, Giallongo C, Di Bartolo O, Spina P, Fiumara P, Schinocca L, Conticello C, Chiarenza A, et al. Myeloid-Derived Suppressor Cells in Patients with Hodgkin Lymphoma. ASH Annual Meeting Abstracts 2009; 114:3662.
57. Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 2009; 9:900-9; PMID:19336265; http://dx.doi. org/10.1016/j.intimp.2009.03.015
58. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C, Ghiringhelli F. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010; 70:3052-61; PMID:20388795; http://dx.doi.org/10.1158/0008-5472.CAN-09-3690
59. Tongu M, Harashima N, Monma H, Inao T, Yamada T, Kawauchi H, Harada M. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol Immunother 2013; 62:383-91; PMID:22926062; http://dx.doi.org/10.1007/ s00262-012-1343-0
60. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, et al. Anticancer chemotherapyinduced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013; 38:729-41; PMID:23562161; http://dx.doi.org/10.1016/j. immuni.2013.03.003
61. Ribatti D, Nico B, Ranieri G, Specchia G, Vacca A. The role of angiogenesis in human non-Hodgkin lymphomas. Neoplasia 2013; 15:231-8; PMID:23479502
62. Passam FH, Alexandrakis MG, Moschandrea J, Sfiridaki A, Roussou PA, Siafakas NM. Angiogenic molecules in Hodgkin's disease: results from sequential serum analysis. Int J Immunopathol Pharmacol 2006; 19:161-70; PMID:16569354
63. Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, Sudhakar A, Kalluri R. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 2004; 64:1570-4; PMID:14996710; http://dx.doi.org/10.1158/0008-5472.CAN-03-3126
64. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 2003; 100:12917-22; PMID:14561896; http://dx.doi.org/10.1073/ pnas.2135406100
65. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003; 63:4342-6; PMID:12907602
66. Mainetti LE, Rico MJ, Fernández-Zenobi MV, Perroud HA, Roggero EA, Rozados VR, Scharovsky OG. Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas. Ann Oncol 2013; 24:2310-6; PMID:23666914; http://dx.doi. org/10.1093/annonc/mdt164
67. Shen FZ, Wang J, Liang J, Mu K, Hou JY, Wang YT. Low-dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells? Int J Exp Pathol 2010; 91:10-6; PMID:20096070; http://dx.doi. org/10.1111/j.1365-2613.2009.00684.x
68. Rozados VR, Sánchez AM, Gervasoni SI, Berra HH, Matar P, Graciela Scharovsky O. Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity. Ann Oncol 2004; 15:1543-50; PMID:15367416; http:// dx.doi.org/10.1093/annonc/mdh384
69. Shamash J, Walewski J, Apostolidis J, Wilson AM, Foran JM, Gupta RK, Rohatiner AZ, Kelsey SM, Lister TA. Low-dose continuous chemotherapy (LBCMVD-56) for refractory and relapsing lymphoma. Ann Oncol 2000; 11:857-60; PMID:10997814; http://dx.doi. org/10.1023/A:1008355417445
70. Coleman M, Ruan G, Elstrom RL, Martin P, Leonard JP. Metronomic therapy for refractory/ relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen. Hematology 2012; 17(Suppl 1):S90-2; PMID:22507790
71. Young SD, Whissell M, Noble JC, Cano PO, Lopez PG, Germond CJ. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin Cancer Res 2006; 12:3092-8; PMID:16707607; http://dx.doi. org/10.1158/1078-0432.CCR-05-2255
72. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56:641-8; PMID:16960692; http://dx.doi. org/10.1007/s00262-006-0225-8
73. Di Nicola M, Zappasodi R, Carlo-Stella C, Mortarini R, Pupa SM, Magni M, Devizzi L, Matteucci P, Baldassari P, Ravagnani F, et al. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood 2009; 113:18-27; PMID:18809757; http://dx.doi.org/10.1182/ blood-2008-06-165654
74. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011; 29:2787-94; PMID:21632504; http://dx.doi.org/10.1200/ JCO.2010.33.3005
75. Song W, Levy R. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells. Cancer Res 2005; 65:5958-64; PMID:15994975; http://dx.doi.org/10.1158/0008-5472.CAN-05-0406
76. Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S, Krieg AM, Levy R. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol 2007; 179:2493-500; PMID:17675511
77. Mattarollo SR, West AC, Steegh K, Duret H, Paget C, Martin B, Matthews GM, Shortt J, Chesi M, Bergsagel PL, et al. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. Blood 2012; 120:3019-29; PMID:22932803; http://dx.doi.org/10.1182/ blood-2012-04-426643
78. Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary MM, Biedrzycki B, Wolff AC, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colonystimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 2009; 27:5911-8; PMID:19805669; http://dx.doi.org/10.1200/ JCO.2009.23.3494
79. Soriano JL, Batista N, Santiesteban E, Lima M, González J, García R, Zarza Y, López MV, Rodríguez M, Loys JL, et al. Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer. Int J Breast Cancer 2011; 2011:710292; PMID:22295231; http://dx.doi. org/10.4061/2011/710292
80. Kandalaft LE, Powell DJ Jr., Chiang CL, Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Torigian DA, et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2013; 2:e22664; PMID:23482679; http://dx.doi. org/10.4161/onci.22664